ALBANY, N.Y., March 30, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2015. A copy of the Annual Report on Form 10-K is available to be viewed or downloaded within the Investor Relations section of the Company's website at www.amriglobal.com.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-filing-of-annual-report-on-form-10k-300243285.html